Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472243 | 0.84 | RXRA (0.40) | HNF4ARXRARARARARBRARG | |
| SCHEMBL4948545 | 0.80 | HNF4A (0.33) | HNF4ARXRARARARARBRARG | |
| SCHEMBL4943229 | 0.78 | HNF4A (0.32) | HNF4ARXRA | |
| SCHEMBL19639459 | 0.72 | PTGDR (0.44) | RARARARBRARG | |
| SCHEMBL5050687 | 0.68 | CYP3A4 (0.47) | HNF4ARXRARARARARBRARG | |
| SCHEMBL19639512 | 0.66 | RARA (0.43) | RARARARBRARG | |
| SCHEMBL6033027 | 0.66 | RARG (0.43) | RARARARBRARG | |
| SCHEMBL4859743 | 0.65 | RXRA (0.51) | HNF4ARXRARARARARBRARG | |
| SCHEMBL6032578 | 0.65 | RARA (0.31) | RARARARBRARGTP53CYP1A2 | |
| SCHEMBL3062968 | 0.65 | FDPS (0.38) | HNF4ARXRARARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
| EP-1513803-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101945-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | HNF4A 876/4885RXRA 4/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.